Chao H. Huang, MD FACP

Professional Background

I precept and teach medical students, residents and fellows in the field of clinical hematology and medical oncology, with a focus on diagnosis, work up and clinical management, preferring clinical trials. I have a special interest in the field of lung cancer and head and neck cancer, especially in multimodality therapy combining radiation with chemotherapy and immunotherapy.

• University Preparatory Studies, Colegio Rosario , Porto Alegre, Rio Grande do Sul
• MD, Medical Doctor , Univ. Fed. de Rio Grande do Sul, Porto Alegre , Rio Grande do Sul
• Internship, Internal Medicine, Presbyterian Medical Center of Univ of Pennsylvania Health, Philadelphia, , PA
• Residency, Internal Medicine , Presbyterian Medical Center University of Pennsylvania Health System, Philadelphia,, PA
• Presbyterian Medical Center University of Pennsylvania Health System , Philadelphia, PA
• Clinical Fellowship, Hematology & Medical Oncology , Fox Chase Cancer Center and Temple University Hospital
• Other, Fox Chase Cancer Center and Temple University Hospital

• Hematology , American Board of Hematology
• Internal Medicine , American Board Of Internal Medicine
• Kansas License , Kansas
• Medical Oncology , American Board of Medical Oncology
• Pennsylvania, Pennsylvania

• Member American Society of Hematology, Member, 2003 - Present
• Southwest Oncology Group, Member, 2003 - Present
• American Society of Clinical Oncology, Member, 1999 - Present
• Member American Association for Cancer Research , Member, 1998 - Present
• American College of Physicians, Member, 1994 - Present

---

• S1800A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) versues Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (lung-MAP Non-matched Sub-Study), SWOG-NCI, PI
• Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC), Alliance for Clinical Trials in Oncology, PI
• Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers, ECOG, PI
• A Phase 3, Controlled, Open-label Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Carcinoma, EpicentRx, PI
• A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma, Trizell, PI

• Islam K.M., Deviany PoppyE., Anggondowati Trisari, Ryan JuneE., Fetrick Ann, Bagenda Danstan, Copur MehmetS., Tolentino Addison, Vaziri Irfan, McKean HeidiA., Dunder Steven, Gray JhanelleE., Huang ChaoM.D., Ganti AparKishor. 2019. Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer. Journal of Oncology Practice, 15 (9), e758-e768. http://dx.doi.org/10.1200/jop.18.00734
• Huang ChaoH. 2019. Lung Cancer: Lung Cancer Regional Snapshot Kansas City VA Medical Center. Federal Practitioner
• 2018. Randomized Phase 2 Study of Tivantinib Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer. Lung Cancer (117), 44-49
• Park John, McPike Veronica, Kambhampati Suman, Huang Chao, Fields-Meehan January, Verkruyse Linda, Allen Ace , Reddy Eashwer. 2018. Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA. Fed Pract.. https://www.mdedge.com/fedprac/avaho/article/166785/head-neck-cancers/positivity-rates-oropharyngeal-and-nonoropharyngeal
• Komiya Takefumi, Huang ChaoH. 2018. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2, 3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. Frontier Oncology. https://doi.org/10.3389/fonc.2018.00423
• Gerber DavidE, Socinski MarkA, Neal JoelW, Wakelee HeatherA, Shirai Keisuke, Sequist LeciaV, Rosovsky et al. RachelP. 2018. Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. Lung Cancer, 117, 44-49
• Weng Fen, Sood Sumit, Yap Wendall, Madan Rashna, TenNapel Mindi, Shen Xinglei, Huang ChaoH, Chen Allen. 2018. Early-Stage Lung Adenocarcinoma treated with Stereotactic Body Radiation Therapy (SBRT)
• Haque Inamul, Motes Hannah, Sharma Mukut, Borrego Emma, Reyes Diaz, Godwin AndrewK, Huang Chao H. 2018. - Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Y Volume 59 Y April 2018